drugset / Trial / NCT02171039

Relative Bioavailability of Dabigatran and Atorvastatin in Healthy Male and Female Volunteers

NCT02171039

Phase 1 Completed 24 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

To investigate the bioavailability of dabigatran with and without concomitant administration of atorvastatin and the bioavailability of atorvastatin with and without concomitant administration of dabigatran etexilate

Timeline

Start
2006-06
Primary completion
2006-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 80 mg Oral
Subject Dabigatran Unknown 150 mg Oral

Indications

No indication recorded.